Last reviewed · How we verify
JPI-289 Low-dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
JPI-289 Low-dose (JPI-289 Low-dose) — Jeil Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JPI-289 Low-dose TARGET | JPI-289 Low-dose | Jeil Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JPI-289 Low-dose CI watch — RSS
- JPI-289 Low-dose CI watch — Atom
- JPI-289 Low-dose CI watch — JSON
- JPI-289 Low-dose alone — RSS
Cite this brief
Drug Landscape (2026). JPI-289 Low-dose — Competitive Intelligence Brief. https://druglandscape.com/ci/jpi-289-low-dose. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing